|1.||Butler, Andrew A: 8 articles (03/2014 - 04/2003)|
|2.||Perretti, Mauro: 7 articles (08/2014 - 10/2002)|
|3.||Getting, Stephen J: 6 articles (11/2014 - 10/2002)|
|4.||Hruby, Victor J: 6 articles (10/2011 - 01/2003)|
|5.||Grieco, Paolo: 5 articles (11/2014 - 09/2003)|
|6.||Muceniece, Ruta: 5 articles (01/2010 - 12/2005)|
|7.||Heisler, Lora K: 4 articles (09/2011 - 07/2006)|
|8.||Patel, Hetal B: 4 articles (04/2011 - 12/2008)|
|9.||Dambrova, Maija: 4 articles (01/2010 - 12/2005)|
|10.||Sutton, Gregory M: 4 articles (10/2009 - 05/2006)|
|1.||Body Weight (Weight, Body)
03/01/2013 - "These studies tested whether injection of melanocortin receptor agonists and antagonists directly into the ventral tegmental area (VTA) of adult rats affects feeding and body weight. "
03/11/1999 - "The mahogany (mg) mutation suppresses the effects of lethal yellow on pigmentation and body weight, and results of our previous genetic studies place mg downstream of transcription of Agouti but upstream of melanocortin receptors. "
03/01/2013 - "In addition, chronic blockade of melanocortin receptors in the VTA increased feeding, body weight, and caloric efficiency. "
11/13/2009 - "These melanocortin receptors (MCRs) regulate pigmentation and body weight, respectively. "
04/01/2006 - "Thus, the regulation of constitutive activity of melanocortin receptors is important for the normal control of pigmentation and body-weight homeostasis."
09/03/2013 - "Companion studies published in Science (Asai et al., 2013; Sebag et al., 2013) establish a role for melanocortin receptor accessory protein 2 (Mrap2) in regulating melanocortin receptor activity and in the development of obesity in zebrafish, rodents, and humans."
10/01/1997 - "Linkage and association studies between the melanocortin receptors 4 and 5 genes and obesity-related phenotypes in the Québec Family Study."
03/01/2014 - "Neural melanocortin receptors in obesity and related metabolic disorders."
05/01/2012 - "Numerous mutations of the human melanocortin receptor type 4 (MC4R) gene are responsible for monogenic obesity, and some of them appear to be associated with predisposition or resistance to polygenic obesity. "
05/01/2011 - "Melanocortin receptor-mediated effects on obesity are distributed over specific hypothalamic regions."
04/01/2003 - "Differential role of melanocortin receptor subtypes in cachexia."
08/01/2012 - "Changes in the melanocortin receptors in the hypothalamus of a rat model of cancer cachexia."
12/01/2010 - "Genetic or pharmacological blockade of melanocortin receptor signaling preserves lean body mass and attenuates anorexia in experimental models of cachexia. "
03/01/2007 - "Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice."
03/01/2006 - "Thus, melanocortin receptor antagonism may provide a novel therapeutic strategy for inflammation-associated cachexia in CKD."
|4.||Weight Loss (Weight Reduction)
08/01/2001 - "Our data suggest that a melanocortin receptor agonist can induce weight loss by increasing energy expenditure and promoting body fat utilization in addition to its inhibitory effects on food intake in both obese and lean Zucker rats."
01/01/2001 - "Activation of central melanocortin receptors inhibits feeding and leads to weight loss, whereas blockade of the central melanocortin signaling pathway increases food consumption and promotes weight gain. "
01/01/2006 - "While the development of most (but not all) neuropeptide Y inhibitors as monotherapy interventions have demonstrated limited efficacy thus far, it is possible that the combination of a neuropeptide Y inhibitor with a selective melanocortin receptor ligand may provide improved weight loss over that of either agent alone. "
10/01/2005 - "Increased melanocortin receptor stimulation following leptin administration plays an important role in leptin-induced hypophagia and increased sympathetic nervous system activity and is partly responsible for leptin-induced weight loss. "
05/01/1999 - "In young nonobese animals, melanocortin receptor blockade associated with the Ay mutation causes complete resistance to leptin-induced weight loss. "
|5.||Wounds and Injuries (Trauma)
04/01/2006 - "These observations suggest that non-peptide compounds with varying affinity to melanocortin receptors are able to influence the pathophysiology of SCI. Furthermore, compounds acting at melanocortin, MCR4 receptors are capable to induce neuroprotection in spinal cord following trauma."
01/01/2003 - "These observations suggest that the non-peptide compound ME10501 with affinity to the melanocortin receptor MC4 is capable to induce neuroprotection in the spinal cord following trauma not reported earlier."
03/01/2006 - "Treatment with nanomolar doses of the melanocortin analog [Nle4, D-Phe7] alpha-MSH [which activates the melanocortin receptor subtypes (MC) mainly expressed in central nervous system, namely MC3 and MC4] modulated the inflammatory and apoptotic cascades and reduced hippocampus injuries even when delayed up to 9 h after ischemia, with consequent dose-dependent improvement in subsequent functional recovery. "
|6.||Nitric Oxide (Nitrogen Monoxide)
|8.||Type 4 Melanocortin Receptor (Melanocortin-4 Receptor)
|9.||Melanocyte-Stimulating Hormones (MSH)